Colloques de l'ISG
The next "Colloque de l'ISG" will take place on :
- April 18th, 2023
- from 11:45 am to 01:45 pm (Lunch 11:45 am - 12:15 pm / Talk 12:15 pm -01:45 pm)
- Meeting Room Institute of Global Health G6-02
- Registration mandatory by Limesurvey registration here or by email : contact-igh@unige.ch
- This presentation validates 2 credits in Prevention and Public Health
Mrs. Marisol Touraine, Chair of Unitaid Executive Board, Former Minister of Health, Social Affairs and Women Rights; Dr. Philippe Duneton, Executive Director of Unitaid
Billions of dollars are spent each year on developing critical health innovations, yet far less is invested to ensure they reach everyone who needs them. High prices, regulatory obstacles, mal-adapted products, evidence gaps, or a lack of quality assurance, among many other factors, keep most health innovations from reaching people in low- and middle-income countries for years – often for more than a decade. With time running out to reach the health targets set forth in the Sustainable Development Goals and recover progress lost to the COVID-19 pandemic, we cannot afford to waste a minute, let alone a decade. Innovations are critical to advancing health responses to HIV, tuberculosis, malaria, women and children’s health and global health emergencies, but access is the key to our collective success. This is where Unitaid comes in.
********************************************************************************************************
- April 26th, 2023
- from 11:45 am to 01:45 pm (Lunch 11:45 am - 12:15 pm / Talk 12:15 pm -01:45 pm)
- Meeting Room Institute of Global Health G6-02
- Registration mandatory by Limesurvey registration here or by email : contact-igh@unige.ch
- This presentation validates 2 credits in Prevention and Public Health
How are Real World Data (RWD) and Real World Evidence (RWE) transforming clinical research and healthcare ?
Mr. Daniel Muscionico, PharmD, MPH, MBA
Real World Data (RWD) and Real World Evidence (RWE) are revolutionizing healthcare by providing valuable insights into patient health and treatment outcomes. This technology is transforming personalized medicine, clinical trials, population health management, and patient engagement. By analyzing vast amounts of data from real-world sources such as electronic health records, insurance claims, and other sources, healthcare providers can tailor treatment plans to individual patients based on their unique medical history, genetic makeup, and lifestyle factors. Moreover, RWE is increasingly being used to support clinical trial design and regulatory decision-making, resulting in better understanding of the safety and efficacy of drugs and medical devices.
Regulators such as FDA, EMA have recently published guidelines on how to best use RWE to accelerate clinical research. This is an exciting time for healthcare, and RWD and RWE are at the forefront of how important changes in our health systems.